hydration effects glp-1 receptor agonist therapy 2025 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies The dual impact of GLP-1
Description
doi: 10.1016/j.npep.2017.04.006
TIX100 is already FDA IND-cleared in diabetes and has demonstrated Phase 1 safety in healthy volunteers
Samanc B, Samanc Y, Tzn E, et al
Still, careful monitoring of thyroid function and medication requirements remains critical, especially in the context of significant weight loss
reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech/Roche and Novartis
